ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA – Free Report) – Stock analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for ImmunoPrecise Antibodies in a research note issued to investors on Tuesday, September 17th. HC Wainwright analyst S. Ramakanth expects that the company will earn ($0.08) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for ImmunoPrecise Antibodies’ current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for ImmunoPrecise Antibodies’ Q2 2026 earnings at ($0.02) EPS, Q3 2026 earnings at ($0.04) EPS, Q4 2026 earnings at ($0.02) EPS, FY2027 earnings at ($0.01) EPS, FY2028 earnings at $0.14 EPS and FY2029 earnings at $0.32 EPS.
Separately, Benchmark lowered their target price on ImmunoPrecise Antibodies from $5.00 to $3.00 and set a “speculative buy” rating on the stock in a research note on Wednesday, August 14th.
ImmunoPrecise Antibodies Stock Up 14.0 %
Shares of IPA opened at $0.66 on Wednesday. ImmunoPrecise Antibodies has a 52 week low of $0.53 and a 52 week high of $2.60. The company has a quick ratio of 1.15, a current ratio of 1.41 and a debt-to-equity ratio of 0.36. The company has a market capitalization of $17.37 million, a price-to-earnings ratio of -1.61 and a beta of 0.10. The stock’s 50-day moving average price is $0.79 and its 200-day moving average price is $1.09.
ImmunoPrecise Antibodies (NASDAQ:IPA – Get Free Report) last issued its earnings results on Monday, July 29th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.42). ImmunoPrecise Antibodies had a negative return on equity of 57.05% and a negative net margin of 110.66%. The company had revenue of $4.76 million during the quarter, compared to analysts’ expectations of $4.92 million.
Hedge Funds Weigh In On ImmunoPrecise Antibodies
A hedge fund recently raised its stake in ImmunoPrecise Antibodies stock. Renaissance Technologies LLC increased its holdings in ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA – Free Report) by 70.0% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 63,910 shares of the company’s stock after purchasing an additional 26,310 shares during the quarter. Renaissance Technologies LLC owned 0.24% of ImmunoPrecise Antibodies worth $65,000 at the end of the most recent reporting period. 6.70% of the stock is owned by institutional investors and hedge funds.
About ImmunoPrecise Antibodies
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.
Further Reading
- Five stocks we like better than ImmunoPrecise Antibodies
- 5 discounted opportunities for dividend growth investors
- How Much Can You Make in Stocks in One Month?
- Buy P&G Now, Before It Sets A New All-Time High
- This Is the Top Large-Cap Stock Insiders Are Buying
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Receive News & Ratings for ImmunoPrecise Antibodies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoPrecise Antibodies and related companies with MarketBeat.com's FREE daily email newsletter.
